Mary Fitzpatrick, ANP, MSCN Michelle Cameron, MD, PT

Transcription

1

2 Mary Fitzpatrick, ANP, MSCN Michelle Cameron, MD, PT

3 This continuing education activity is managed and accredited by Professional Education Service Group. The material presented in this activity represents the opinion of the faculty. Neither PESG, nor any accrediting organization endorses any commercial products displayed in conjunction with this activity. Commercial Support was not received for this activity.

4 Michelle Cameron, MD, PT has received research support from Acorda Therapeutics Mary Fitzpatrick, ANP, has attended and been compensated for a Biogen-Idec nurse advisory meeting CME Staff Disclosures Professional Education Services Group staff have no financial interest or relationships to disclose

5 At the conclusion of this activity, the participant will be able to: Describe the nature of gait and balance impairments common in Veterans with MS Recognize Veterans with MS with gait and balance impairments Recommend interventions to improve walking and reduce fall risk in Veterans with MS

6 Background Walking impairment in MS Nature of walking impairments in MS Treatment of slowed walking in Veterans with MS A VA experience with dalfampridine Falls and Imbalance in MS Prevalence and incidence of falls in MS Falls in Veterans with MS Management of imbalance and falls in MS

7 CNS disorder (brain, spinal cord, optic nerves) Symptoms separated in time and space Complex immune-mediated disorder

8

9 Very varied initial presentation Reduced sensation (33%*) Visual changes vision loss (16%), diplopia (7%) Weakness (13%) Unsteadiness when walking (5%) Poor balance (3%) Multiple symptoms (15%) Also Spasticity Incontinence Cognitive changes All of these can affect walking and balance

10 Compared with health controls, people with MS: Walk more slowly Have reduced gait endurance Have reduced community mobility Take shorter steps Step more slowly Have less joint movement during gait Have more variability in most gait parameters Slow down more when performing a cognitive task

11

12 Sensory changes particularly proprioception Lower extremity weakness Lower extremity spasticity Cerebellar ataxia

13 Timed measures Timed 25-Foot Walk Test (for speed) 6-minute/2-minute walk test (for endurance) Timed Up and Go (for functional speed) Patient Reported Outcomes Multiple Sclerosis Walking Scale-12 a patient-based measure of the impact of MS on walking Observational Gait Analysis Watch them walk

14 Instrumented walkway Gait lab Gyroscopes and accelerometers

15

16

17

18 Objectives: For a 12 month cohort of patients with MS prescribed dalfampridine at a VA Medical Center, to determine tolerability and effects of dalfampridine on: walking speed, (Timed 25 foot walk) self-perceived impact of multiple sclerosis (MS) on walking, (MSWS-12) walking endurance, (2 minute timed walk) community participation, (Community Integration Questionnaire)

19 01/22/2010 the FDA approved dalfampridine to improve walking in patients with MS Based on research demonstrating improved walking speed on the timed 25-foot walk test (T25FWT) self-perceived walking using the Multiple Sclerosis Walking Scale-12 (MSWS-12). Since dalfampridine became clinically available, no analyses of its real-world tolerability or effectiveness have been published.

20 All patients prescribed dalfampridine at the Portland VA Medical Center from 10/01/10-09/30/11 T25FTW, MSWS-12, two minute timed walk (2MTW) Community Integration Questionnaire (CIQ) Baseline assessment prior to taking dalfampridine. Individuals reporting a favorable response to dalfampridine at 3-4 weeks continued to take the drug All measures repeated at 1-4 months and at follow-up MS clinic visits. Measures were compared with baseline using paired t- tests.

21 Time (seconds) 25 Foot Timed Walk Mean: ± 9.55 N = 23 Mean: ± 6.18 N = 22, P = Mean: 9.40 ± 2.75 N = 16, P = Baseline 1-4 months 5-10 months

22 Score MS Walking Scale Mean: N=22 Mean: ± N = 22, P = Mean: ± 9.53 N = 6, P = Baseline 1-4 months 5-10 months

23 Distance (feet) Two Minute Timed Walk Mean: ± N=20 Mean: ± 99.94, N = 16, P = Mean: ± N = 7, P = Baseline 1-4 months 5-10 months

24 Score Community Integration Questionnaire Mean: ± 3.58 N=21 Mean: ± 3.72, N = 20, P = Mean: ± 3.86 N = 4, P = Baseline 1-4 months 5-10 months

25 1. 39 individuals were prescribed dalfampridine during the 12 month period analyzed individuals (58%) continued beyond the initial 3-4 week trial individuals (42%) stopped within 3-4 weeks due to intolerance and/or perceived lack of efficacy. There were no serious AEs. 4. Walking speed, endurance and self-perceived walking improved significantly at 1-4 month follow-up. 5. There was a trend towards improvement in walking speed and self-perceived walking at 5-10 month follow-up.

26 Walking speed, endurance, and self-perceived walking were improved at 1-4 months with dalfampridine. Community participation was not significantly improved at 1-4 month follow-up. More complete follow-up of the sample is needed to reliably and validly assess longer term impacts

27 >75% complain of balance abnormalities >50% fall in 3 months 12% had an injurious fall in 6 months 50% with an injurious fall ever Balance abnormalities occur in those with minimal or undetectable impairments, as well as in those with significant impairments

28 Balance control of center of mass over base of support Postural control - Control of the body s position in space, when stationary or moving Fall unintentional change in position resulting in coming to rest on the ground or at a lower level

29

30

31 % Falls in 12 months How many people with MS fall? 489 Neurology inpatients 34% had fallen in the last year 32% of those with MS had fallen in the last year PD Sync PNP EPIL SD MND MS PSY Stroke Pain Neurological Diagnosis PD Parkinson s disease Sync Syncope PNP Polyneuropathy SD Spinal disorders EPIL Epilepsy MND Motor neuron disease MS Multiple sclerosis PSY Psychogenic Falls in Frequent Neurological Diseases, Stolze et al J Neurology, 251:79-84, 2004

32 Risk of Falls in Subjects with MS Cattaneo D, DeNuzzo C, Fascia T, et al. Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil. 2002;83(6): people with MS in Italy 54% (27/50) reported 1 or more falls in the previous 2 months 32% (17/50)reported 2 or more falls in the previous 2 months

33 Falling in People with MS Aged years Finlayson, ML, Peterson EW. Arch Phys Med Rehabil. 2006;87: ,089 people with MS in the Midwest US 52% reported falling at least once in the prior 6 months Nilsagard, 48/76 (63%) people with MS in Sweden recorded 270 falls in 3 months

34 58 people with MS in Portand falls in 2 mo - # who fell 30/58 (52%) # w/ 2 falls - 16/58 (28%) falls in 12 mo # who fell 43/58 (74%) # w/ 2 falls - 36/58 (62%) # w/ > 10 falls - 5/58 (9%)

35 Falls in Veterans with MS in VISN20 195,417 Veterans in VISN20 (NW USA), 721 with MS Unadjusted odds of an injurious fall was 1.9 times higher in veterans with MS than in veterans without MS For females: Odds were 3 times higher for veterans with MS than for veterans without MS (OR 3.0, 95% CI ) For males: Odds were 1.2 times higher for veterans with MS than for veterans without MS (OR 1.2, 95% CI )

36 Fear of falling Injuries and death Impaired balance Impaired walking Use of a walking aide Disturbed proprioception Spasticity More severe MS Lower income Leg weakness

37 Divided attention Reduced muscular endurance Fatigue Heat sensitivity

38 Have you fallen in the last year? Questionnaires Activities-specific Balance Confidence (ABC) Falls Efficacy Scale (FES) Dizziness Handicap Inventory (DHI) Fall diaries Romberg Clinical Tests Berg Balance Scale Functional Reach Balance Evaluation Systems Test (BESTest)

39

40 Based on General common pathophysiology Somatosensory dysfunction Impaired central integration Individual examination and assessment

41 Gait assistive devices Exercise/balance training Safety strategies Home modifications

42 Enhance input TENS, strap or brace on leg Light touch cane Auditory input Tongue stimulation Practice Substitution Increase reliance on vision and vestibular Avoidance Avoid low light Avoid uneven surfaces

43 A cane or hiking poles to provide proprioceptive information more than support

44 Light touch increases proprioceptive input No Touch Light Touch Heavy Touch A-P M-L Center of Pressure M-L M-L Dickstein and Horak Gait and Posture, 2000

45 Practice Dual task Avoid Dual/multiple task

46 Walking and talking Walking and head turns Walking and visual distraction Walking and auditory distraction

47

48

49 Foot wear Home hazards Lights Trips

50

51

52

53 Many Veterans with MS have impaired walking and poor balance and fall frequently There are many ways to assess gait and imbalance in Veterans with MS Interventions to improve gait and imbalance in Veterans with MS include: Medications Devices Exercise Environmental modifications

54

55 If you would like to receive continuing education credit for this activity, please visit: